The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...
After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...
US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...
GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review, data from the MATINEE study to support the regulatory ...
British drug maker GSK plc (GSK, GSK.L) announced Monday that the U.S. Food and Drug Administration has accepted for review, data ...
GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...
It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...
GlaxoSmithKline’s lung disease drug Nucala is unlikely to receive US approval for chronic obstructive pulmonary disease (COPD), following judgements made by advisers. The FDA's Pulmonary-Allergy ...
London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...
With competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes will keep its Nucala drug ahead of its rivals. The European Commission has approved ...
London open The FTSE 100 is expected to open eight points higher on Monday, having closed down 0.49% on Friday at 8,308.61.
In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...